{"html": "<!DOCTYPE html>\n<html>\n<head>\n\t<meta charset=\"UTF-8\">\n\t<script type=\"text/javascript\">\n\tvar methode = {};\n\tmethode.freeviewCount = 1;\n\tmethode.freeviewCountIncremented = true;\n\tmethode.showPaywall = false;\n\tmethode.subscribed = false;\n\tmethode.debug = false;\n\tmethode.freetrial = false;\n\twindow.globe = window.globe || {};\n\tglobe.version = '17033I1505';\n</script><!-- /business auto:  -->\n\t<title>Hope for devastating child disease comes at a cost: $750,000 a year - The Boston Globe</title>\r\n<meta name=\"eomportal-instanceid\" content=\"29\"/>\r\n<meta name=\"eomportal-id\" content=\"748128\"/>\r\n<meta name=\"eomportal-loid\" content=\"4.3.820447928\"/>\r\n<meta name=\"eomportal-uuid\" content=\"5a3433ec-135f-11e7-9d9d-b50c0a22aa93\"/>\r\n<meta name=\"eomportal-lastUpdate\" content=\"Mon Mar 27 23:55:52 EDT 2017\"/>\r\n<title>Hope for devastating child disease comes at a cost: $750,000 a year - The Boston Globe</title>\r\n<!-- Methode uuid: \"5a3433ec-135f-11e7-9d9d-b50c0a22aa93\" -->\r\n<script src=\"//cdn.blueconic.net/bostonglobemedia.js\"></script>\n\n\t<meta property=\"og:type\" content=\"article\"/>\n\t<meta property=\"og:description\" content=\"Parents of children with a rare disease called spinal muscular atrophy were thrilled two days before Christmas, when regulators approved the first drug to treat the condition that often kills patients before their second birthday.\nBut in the three months since, some parents in Massachusetts have fought to get their insurer, Neighborhood Health Plan, to pay for the medicine, an enormously expensive drug called Spinraza and made by Cambridge-based Biogen Inc.\"/>\n\t<meta property=\"og:title\" content=\"Hope for devastating child disease comes at a cost: $750,000 a year - The Boston Globe\"/>\n\t<meta property=\"og:site_name\" content=\"BostonGlobe.com\" />\n\t<meta property=\"fb:admins\" content=\"100001044693856\" />\n\t<meta property=\"fb:admins\" content=\"507486035\" />\n\t<meta property=\"fb:app_id\" content=\"103933749691726\" />\n\t<meta property=\"fb:pages\" content=\"5637143257\" />\n\t<meta property=\"article:publisher\" content=\"https://www.facebook.com/globe\" />\n\t<link rel=\"apple-touch-icon\" href=\"//c.o0bg.com/rw/SysConfig/WebPortal/BostonGlobe/Framework/images/bookmark-114.png\"/>\n\t<link rel=\"shortcut icon\" type=\"image/gif\" href=\"/rw/SysConfig/WebPortal/BostonGlobe/Framework/images/favicon.ico\" />\n\n\t<!--[if gte IE 9 ]>\n\t<meta name=\"application-name\" content=\"Homepage\"/>\n\t<meta name=\"msapplication-tooltip\" content=\"This is the tooltip\"/>\n\t<meta name=\"msapplication-starturl\" content=\"/?comp=9\"/>\n\t<![endif]-->\n\n\t<!--[if lte IE 8 ]>\n\t<meta name=\"application-name\" content=\"Boston Globe\"/>\n\t<meta name=\"msapplication-TileColor\" content=\"#000000\"/>\n\t<meta name=\"msapplication-TileImage\" content=\"25a75e8d-4542-40a4-80aa-253aea7efc28.png\"/>\n\t<link rel=\"stylesheet\" media=\"print\" href=\"/css/globe-ie-print.css?v=17033I1505\" type=\"text/css\" />\n\t<![endif]-->\n\n\t<meta property=\"twitter:account_id\" content=\"95431448\" />\n<meta name=\"robots\" content=\"noarchive\" />\n<meta name=\"description\" content=\"Parents of children with a rare disease called spinal muscular atrophy were thrilled two days before Christmas, when regulators approved the first drug to treat the condition that often kills patients before their second birthday.\nBut in the three months since, some parents in Massachusetts have fought to get their insurer, Neighborhood Health Plan, to pay for the medicine, an enormously expensive drug called Spinraza and made by Cambridge-based Biogen Inc.\" />\n<meta name=\"keywords\" content=\"biogen,spinraza,neighborhood health plan,spinal muscular atrophy,SMA,Partners HealthCare,Boston Children's Hospital,Jim Farrell,Health Policy Commission,Food and Drug Administration, Aetna Incorporated, Blue Cross and Blue Shield, Twitter, Children's Hospital,Aetna Incorporated|AET|NYSE\" />\n<meta name=\"news_keywords\" content=\"biogen,spinraza,neighborhood health plan,spinal muscular atrophy,SMA,Partners HealthCare,Boston Children's Hospital,Jim Farrell,Health Policy Commission,Food and Drug Administration\" />\n<meta property=\"og:url\" content=\"https://www.bostonglobe.com/business/2017/03/27/spinraza/QnBmQrcmLLfUwvJunn0P8K/story.html\"/>\n<link rel=\"canonical\" href=\"https://www.bostonglobe.com/business/2017/03/27/spinraza/QnBmQrcmLLfUwvJunn0P8K/story.html\" />\n<meta name=\"twitter:card\" content=\"summary_large_image\" />\n<meta name=\"twitter:site\" content=\"BostonGlobe\" />\n<link rel=\"amphtml\" href=\"https://www.bostonglobe.com/business/2017/03/27/spinraza/QnBmQrcmLLfUwvJunn0P8K/amp.html\" />\n\t<meta property=\"og:image\" content=\"http://www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza5biz.jpg\" />\n<meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge,chrome=1\" />\n<meta name=\"viewport\" content=\"width=device-width, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no\" /> <!--[if gte IE 6]><link href=\"/css/html5reset.css,globe-globals.css,globe-masthead.css,globe-nav.css,globe-nav-menus.css,globe-main.css,globe-footer.css,globe-print.css\" rel=\"stylesheet\"><![endif]-->\n<!--[if !IE]><link href=\"/css/html5reset.css,globe-globals.css,globe-masthead.css,globe-nav.css,globe-nav-menus.css,globe-main.css,globe-footer.css,globe-print.css?v=17033I1505\" rel=\"stylesheet\" media=\"only all\"><![endif]-->\n<script src=\"/js/lib/rwd-images.js,lib/respond.min.js,lib/modernizr.custom.min.js,globe-define.js,globe-controller.js?v=17033I1505\"></script>\n\t<script type=\"text/javascript\" title=\"https://iconizr.com | \u00a9 2014 Joschi Kuphal | MIT\">!function(){var a=window,b=a.document,c=arguments,d=\"createElementNS\",e=\"http://www.w3.org/\",f=\"svg\",g=function(a){var g=b.getElementsByTagName(\"script\")[0],h=b.createElement(\"link\");h.rel=\"stylesheet\",h.type=\"text/css\",h.href=c[1*a|2*(b[d]&&b[d](e+\"2000/\"+f,f).createSVGRect&&b.implementation.hasFeature(e+\"TR/SVG11/feature#Image\",\"1.1\"))],g.parentNode.insertBefore(h,g)},h=new a.Image;h.onerror=function(){g(0)},h.onload=function(){g(1===h.width&&1===h.height)},h.src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==\"}(\"/css/icon-png-sprite.css\",\"/css/icon-png-data.css\",\"/css/icon-svg-sprite.css\",\"/css/icon-svg-data.css\");</script>\n\t<noscript>\n\t   <link href=\"/css/icon-png-sprite.css?v=17033I1505\" rel=\"stylesheet\" type=\"text/css\" media=\"all\">\n\t</noscript>\n\n<!-- /business and story -->\n<script src=\"/js/lib/jquery.js,lib/magnific.js,lib/lo-dash-custom-2.4.1.js,globe-modal-meter.js,globe-newsletter.js,globe-topic-nav.js?v=17033I1505\"></script>\n<link rel=\"stylesheet\" type=\"text/css\" media=\"all\" href=\"/css/html5reset.css,globe-globals.css,globe-masthead.css,globe-nav.css,globe-nav-menus.css,globe-main.css,globe-footer.css,modal-login.css,globe-polldaddy.css,article.css,gallery.css,globe-topic-nav.css?v=17033I1505\"/>\n<link rel=\"stylesheet\" type=\"text/css\" media=\"print\" href=\"/css/globe-print.css?v=17033I1505\"/>\n<!-- oas_sitepage:/business/homepage -->\n<!-- webtype is story section is  adPageType article oas_sitepage /business/homepage-->\n\n<!--  lowestRank:  taxonomy:  section:  --> \n\t\t\n\t\t<!-- admode:  smode  -->\n\t\t<script type=\"text/javascript\">\n      var googletag = googletag || {};\n      googletag.cmd = googletag.cmd || [];\n\n      function oxDone() {\n        var gads = document.createElement(\"script\");\n        gads.async = true;\n        gads.type = \"text/javascript\";\n        gads.src = \"//www.googletagservices.com/tag/js/gpt.js\";\n        var node = document.getElementsByTagName(\"script\")[0];\n        node.parentNode.insertBefore(gads, node);\n      }\n\n      \n      var OX_dfp_ads = [];\n\n      (function() {\n        var openx = document.createElement(\"script\");\n        openx.async = true;\n        openx.type = \"text/javascript\";\n\n        // Conditionally load OX based on breakpoint.\n        if ( 768 < window.outerWidth ) {\n            openx.src = \"//boston-d.openx.net/w/1.0/jstag?nc=61381659-bostonglobe-desktop\";\n        } else {\n            openx.src = \"//boston-d.openx.net/w/1.0/jstag?nc=61381659-bostonglobe-mobile\";\n        }\n\n        var node = document.getElementsByTagName(\"script\")[0];\n        node.parentNode.insertBefore(openx, node);\n      })();\n\n       setTimeout(function() {\n           if (!('OX' in window || 'oxhbjs' in window)) {\n               oxDone();\n           }\n       },2500);\n\n    </script>\n\n    <!-- modAdunit: bostonglobe.com/business  -->\n    <script>\n    \t  var globe = globe || {};\n\t      globe.dfp = {\n\t        networkCode: 61381659\n\t      };\n\n          globe.dfp.keyValuePairs = {\n            s1: 'bostonglobe.com',\n            s2: 'business',\n            s3: '',\n            s4: '',\n            pgtype: 'article',\n            pageurl : '_business_2017_03_27_spinraza_QnBmQrcmLLfUwvJunn0P8K_story_html',\n            freetrial: \"n\",\n            logstat: \"n\",\n            sub: \"n\",\n            meta: \"biogen,spinraza,neighborhood_health_plan,spinal_muscular_atrophy,SMA,Partners_HealthCare,Boston_Children\\'s_Hospital,Jim_Farrell,Health_Policy_Commission\",\n            weather: \"\",\n            temp: \"\",\n            aam: \"\"\n        }\n        globe.dfp.adUnit = 'bostonglobe.com/business';\n    </script>\n<!-- Facebook Pixel Code -->\n<script>\n!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()\n{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}\n;if(!f._fbq)f._fbq=n;\nn.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;\nt.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,\ndocument,'script','https://connect.facebook.net/en_US/fbevents.js');\nfbq('init', '884869448226452');\nfbq('track', \"PageView\");</script>\n<noscript><img height=\"1\" width=\"1\" style=\"display:none\"\nsrc=\"https://www.facebook.com/tr?id=884869448226452&ev=PageView&noscript=1\"\n/></noscript>\n<!-- End Facebook Pixel Code -->\n</head>\n\n<body itemscope itemtype=\"http://schema.org/WebPage\" class='type-internal type-article section-business business type-business logged-out'>\n\n<div id=\"contain\">\n<!-- type:EOM::CompoundStory autosection: section class:Business section:/business-->\n<!-- topSection2 /business -->\n\n<header class=\"bg-header clearfix\">\n\t<div class=\"bg-header__subinfo bg-header__subinfo--tablet\">\n\t\t\t<div id=\"subscribe-btn\" class=\"bg-header__subscribe js-open-pop-up subscribe-btn--small\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Header';s.events='event13';s.tl(this,'o','BG Header - Subscribe');\">\n\t\t\t\t\t\t<span>Subscribe</span>Starting at 99 cents\n\t\t\t\t\t</div>\n\t\t\t\t\t<a href=\"/login\" class=\"bg-header__log-in\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar27,events';s.linkTrackEvents='event15';s.eVar27='BG Header';s.events='event15';s.tl(this,'o','BG\tHeader - Log In');\">\n\t\t\t\t\t\tMembers<span>Sign In</span>\n\t\t\t\t\t</a>\n\t</div>\n\n\t    <div id=\"smartbar\" class=\"bg-header__smartbar\" data-hide-on-load=\"true\">\n\t       <a href=\"http://subscribe.bostonglobe.com/B6455/?p1=BGHeader_SmartBar_Marketing_Sub\" class=\"bg-header__smartbar--message\" onClick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar15,channel,prop1';s.linkTrackEvents='none';s.tl(this,'o','BG Header - Smart Bar_Marketing Sub');\">\n\t\t\t<span class=\"bg-header__smartbar--text-bold\">SUBSCRIBE NOW</span> <span class=\"bg-header__smartbar--text\">Get unlimited access to Globe.com today</span></a>\t\n\t</div>\n\t<div class=\"bg-header__menus\">\n\t\t<a href=\"#\" class=\"bg-header__button bg-header__hamburger js-open-menu\" onclick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','BG Menu - Open');\">Menu</a>\n\t\t<a href=\"/?p1=BGHeader_Logo\" class=\"bg-header__button bg-header__home\"></a>\n\t</div>\n\t<div class=\"bg-header__subinfo\" >\n\t\t\t\t\t<div id=\"subscribe-btn\" class=\"bg-header__subscribe js-open-pop-up subscribe-btn--regular\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Header';s.events='event13';s.tl(this,'o','BG Header - Subscribe');\">\n\t\t\t\t\t\t<span>Subscribe</span>Starting at 99 cents\n\t\t\t\t\t</div>\n\t\t\t\t\t<a href=\"/login?p1=BGHeader_LogIn\" class=\"bg-header__log-in\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar27,events';s.linkTrackEvents='event15';s.eVar27='BG Header';s.events='event15';s.tl(this,'o','BG Header - Log In');\">\n\t\t\t\t\t\tMembers<span>Sign In</span>\n\t\t\t\t\t</a>\n\t\t\t\t</div>\n\t\t\t<a href=\"/business?p1=BGHeader_SectionLink\" class=\"bg-header__centerpiece bg-header__logo-wrapper\">\n               <div class=\"bg-header__logo\"></div>\n\t\t\t<div class=\"bg-header__section-front\">Business</div>\n\n\t\t\t</a>\n\t\t<nav class=\"bg-header__takeover\" aria-hidden=\"true\">\n\t\t\t\t<div class=\"bg-header__takeover-full-screen\">\n\t\t\t\t\t<div class=\"bg-header__menu-wrapper\">\n\t   \t\t\t\t\t<div class=\"bg-header__close js-close-menu\">\n\t\t   \t\t\t\t</div>\n\t\t   \t\t\t\t<a href=\"\" class=\"bg-header__home\"></a>\n\t\t\t   \t\t\t<!-- Logged out Subinfo -->\n\t\t\t\t\t\t<div class=\"bg-header__subinfo\">\n\t\t\t\t\t<div id=\"subscribe-btn\" class=\"bg-header__subscribe js-open-pop-up subscribe-btn--takeover\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Menu';s.events='event13';s.tl(this,'o','BG Menu - Subscribe');\">\n\t\t\t\t\t\t<span>Subscribe</span>Starting at 99 cents\n\t\t\t\t\t</div>\n\t\t\t\t\t<a href=\"/login?p1=BGMenu_LogIn\" class=\"bg-header__log-in\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar27,events';s.linkTrackEvents='event15';s.eVar27='BG Menu';s.events='event15';s.tl(this,'o','BG Menu - Log In');\">\n\t\t\t\t\t\tMembers<span>Sign In</span>\n\t\t\t\t\t</a>\n\t\t\t\t</div>\n\t\t\t<a href=\"/?p1=BGMenu_Logo\" class=\"bg-header__logo\"></a>\n\n\t\t\t\t\t\t<div class=\"bg-header__menu\">\n\t\t\t\t\t\t\t<section class=\"bg-header__menu-left\">\n\t\t\t\t\t\t\t\t<ul class=\"bg-header__sections\">\n\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/metro?p1=BGMenu\" class=\"bg-header__link\">Metro</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/sports?p1=BGMenu\" class=\"bg-header__link\">Sports</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/business?p1=BGMenu\" class=\"bg-header__link\">Business & Tech</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/opinion?p1=BGMenu\" class=\"bg-header__link\">Opinion</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/news/politics?p1=BGMenu\" class=\"bg-header__link\">Politics</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/lifestyle?p1=BGMenu\" class=\"bg-header__link\">Lifestyle</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"/arts?p1=BGMenu\" class=\"bg-header__link\">Arts</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"http://www.boston.com/section/cars\" class=\"bg-header__link\"\n\t\t\t\t\t\t\t\t\t\t\t\t\t\ttarget=\"_blank\"\n\t\t\t\t\t\t\t\t\t\t\t\t\t\tonclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Menu - Nav - Cars');\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\tCars</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"http://realestate.boston.com\" class=\"bg-header__link\"\n\t\t\t\t\t\t\t\t\t\t\t\t\t\ttarget=\"_blank\"\n\t\t\t\t\t\t\t\t\t\t\t\t\t\tonclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Menu - Nav - Real Estate');\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\tReal Estate</a>\n\t\t\t\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t\t\t\t</ul>\n\t\t\t\t\t\t\t</section>\n\t\t\t\t\t\t\t<section class=\"bg-header__menu-right\">\n\t\t\t\t\t\t\t\t<div class=\"bg-header__recommended\">\n\t\t\t\t\t\t\t\t\t<p class=\"bg-header__recommended-header\">\n\t\t\t\t\t\t\t\t\t\t\n\t\tMost popular on bostonglobe.com\n\t</p>\n\t\t\t\t\t\t\t\t\t<p class=\"bg-header__recommended-subhead\">Based on what you&#39;ve read recently, you might be interested in theses stories</p>\n\t\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t\t<div class=\"bg-header__suggestions\">\n\t\t<figure class=\"bg-header__suggestion\">\n\t\t\t\t\t<a href=\"//www.bostonglobe.com/news/nation/2017/03/26/two-girls-barred-from-united-flight-for-wearing-leggings/WSVuMJEykxM85db1CCzB2N/story.html?p1=BGMenu_Article\" class=\"bg-header__link\">\n\t\t\t\t          <picture class=\"bg-header__image-wrapper\">\n\t\t\t\t\t\t\t<img class=\"bg-header__suggestion-image\" src=\"//www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/26/BostonGlobe.com/National/Images/united.jpg\"/>\n\t\t\t\t\t\t</picture>\n\t\t\t\t\t\t<figcaption class=\"bg-header__suggestion-title\">Two teenage girls barred from United flight for wearing leggings</figcaption>\n\t \t\t\t\t\t</a>\n\t\t   \t\t\t</figure>\n\t\t\t\t<figure class=\"bg-header__suggestion\">\n\t\t\t\t\t<a href=\"//www.bostonglobe.com/metro/2017/03/26/some-survivors-marathon-bombings-feel-slighted-city/07wJ2PiShpkqm74pW5iKSL/story.html?p1=BGMenu_Article\" class=\"bg-header__link\">\n\t\t\t\t          <picture class=\"bg-header__image-wrapper\">\n\t\t\t\t\t\t\t<img class=\"bg-header__suggestion-image\" src=\"//www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/15/BostonGlobe.com/Metro/Images/kreiter_bombingsurvivor2_met.jpg\"/>\n\t\t\t\t\t\t</picture>\n\t\t\t\t\t\t<figcaption class=\"bg-header__suggestion-title\">Some survivors of the Marathon bombings feel slighted by city</figcaption>\n\t \t\t\t\t\t</a>\n\t\t   \t\t\t</figure>\n\t\t\t\t<figure class=\"bg-header__suggestion\">\n\t\t\t\t\t<a href=\"//www.bostonglobe.com/metro/2017/03/26/caitlyn-rose-kasper-wonders-where-she-comes-from-not-easy-question-answer/4Xr8m4mzjdFgysSeWQjWDL/story.html?p1=BGMenu_Article\" class=\"bg-header__link\">\n\t\t\t\t          <picture class=\"bg-header__image-wrapper\">\n\t\t\t\t\t\t\t<img class=\"bg-header__suggestion-image\" src=\"//www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/02/BostonGlobe.com/Metro/Images/Bedford_170223_CAITLYN_011.jpg\"/>\n\t\t\t\t\t\t</picture>\n\t\t\t\t\t\t<figcaption class=\"bg-header__suggestion-title\">Caitlyn Rose Kasper wonders where she comes from. It\u2019s not an easy question to answer.</figcaption>\n\t \t\t\t\t\t</a>\n\t\t   \t\t\t</figure>\n\t\t\t\t<figure class=\"bg-header__suggestion\">\n\t\t\t\t\t<a href=\"//www.bostonglobe.com/news/politics/2017/03/27/senate-committee-question-jared-kushner-over-russia-meetings/KoBjnnz2YTm1R4a7sIdpEP/story.html?p1=BGMenu_Article\" class=\"bg-header__link\">\n\t\t\t\t          <picture class=\"bg-header__image-wrapper\">\n\t\t\t\t\t\t\t<img class=\"bg-header__suggestion-image\" src=\"//www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/27/BostonGlobe.com/Politics/Images/654568498.jpg\"/>\n\t\t\t\t\t\t</picture>\n\t\t\t\t\t\t<figcaption class=\"bg-header__suggestion-title\">Senate panel to question Jared Kushner over meetings with Russians</figcaption>\n\t \t\t\t\t\t</a>\n\t\t   \t\t\t</figure>\n\t\t\t\t</div>\n<form action=\"/queryResult/search\" class=\"bg-header__search\" method=\"get\" role=\"search\">\n\t\t\t\t\t\t        <div class=\"search-inputs\">\n\t\t\t\t\t\t\t\t\t<input type=\"text\" class=\"bg-header__input\" id=\"q\" placeholder=\"Search BostonGlobe.com\" role=\"search\" name=\"q\">\n\t\t\t\t\t\t\t\t</div>\n\t\t\t\t\t\t\t</form>\n\t\t\t\t\t\t\t</section>\n\t\t\t\t\t\t\t<ul class=\"bg-header__more-sections\">\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"/todayspaper?p1=BGMenu_Subnav\" class=\"bg-header__link\">Today's Paper</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"/magazine?p1=BGMenu_Subnav\" class=\"bg-header__link\">Magazine</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"/metro/obituaries?p1=BGMenu_Subnav\" class=\"bg-header__link\">Obituaries</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"http://www.boston.com/weather?p1=BGMenu_Subnav\" class=\"bg-header__link\">Weather</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"/lifestyle/comics?p1=BGMenu_Subnav\" class=\"bg-header__link\">Comics</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"/lifestyle/crossword?p1=BGMenu_Subnav\" class=\"bg-header__link\">Crossword</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t<li class=\"bg-header__section\">\n\t\t\t\t\t\t\t\t\t\t<a href=\"/news/bigpicture?p1=BGMenu_Subnav\" class=\"bg-header__link\">The Big Picture</a>\n\t\t\t\t\t\t\t\t\t</li>\n\t\t\t\t\t\t\t\t</ul>\n\t\t\t\t\t\t</div>\n\t\t\t\t\t\t<aside class=\"bg-header__pop-up\" aria-hidden=\"true\">\n\t\t\t\t\t   \t\t<div class=\"bg-header__close-pop-up js-close-pop-up\"></div>\n\t\t\t\t\t   \t\t<div class=\"bg-header__caret-wrapper\"><div class=\"bg-header__caret\"></div></div>\n\t\t\t\t\t   \t\t<section class=\"bg-header__pop-up-section bg-header__pop-up-section--digital\">\n\t\t\t\t\t\t   \t\t<img src=\"/img/masthead/lockup.png\" class=\"bg-header__sub-img\"/>\n\t\t\t\t\t   \t\t\t<p class=\"bg-header__sub-title\">Digital Access</p>\n\t\t\t\t\t   \t\t\t<p class=\"bg-header__promo-text\">99 cents a week for the first 4 weeks</p>\n\t\t\t\t\t\t\t\t<a href=\"https://subscribe.bostonglobe.com/B3853/?eglobe_rc=WW20167D&p1=BGMenu_DigitalSubscription\" class=\"bg-header__sub-button bg-header__display-mobile\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Menu Modal';s.events='event13';s.tl(this,'o','BG Menu \u2013 Subscribe Digital');\">Subscribe</a>\n\t\t\t\t\t\t\t\t<a href=\"https://subscribe.bostonglobe.com/B3853/?rc=WW20167D&eglobe_rc=WW20167D&p1=BGMenu_DigitalSubscription\" class=\"bg-header__sub-button bg-header__display-desktop\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Menu Modal';s.events='event13';s.tl(this,'o','BG Menu \u2013 Subscribe Digital');\">Subscribe</a>\t\t\t\t   \t\t\t</section>\n\t\t\t\t\t   \t\t<section class=\"bg-header__pop-up-section bg-header__pop-up-section--delivery\">\n\t\t\t\t\t   \t\t\t<img src=\"/img/masthead/newspaper.png\" class=\"bg-header__sub-img\"/>\n\t\t\t\t\t   \t\t\t<p class=\"bg-header__sub-title\">Home Delivery</p>\n\t\t\t\t\t   \t\t\t<p class=\"bg-header__promo-text\">Save 50% off the regular rate</p>\n\t\t\t\t\t\t\t\t<a href=\"//homedelivery.bostonglobe.com/hd/26/order/zip/?rc=WW011964&globe_rc=WW011964&p1=BGMenu_HomeDeliverySubscription\" class=\"bg-header__sub-button bg-header__display-mobile\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Menu Modal';s.events='event13';s.tl(this,'o','BG Menu \u2013 Subscribe HD');\">Subscribe</a>\n\t\t   \t\t\t\t\t\t<a href=\"https://subscribe.bostonglobe.com/B8554/?rc=WW011964&globe_rc=WW011964&p1=BGMenu_HomeDeliverySubscription\" class=\"bg-header__sub-button bg-header__display-desktop\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG Menu Modal';s.events='event13';s.tl(this,'o','BG Menu \u2013 Subscribe HD');\">Subscribe</a>\n\t\t\t\t\t   \t\t</section>\n\t\t\t\t   \t\t\t<span class=\"bg-header__sub-login\">Already a subscriber? <a href=\"/login?p1=BGMenu_Login_Link\" class=\"bg-header__sub-click\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar27,events';s.linkTrackEvents='event15';s.eVar27='BG Menu Modal';s.events='event15';s.tl(this,'o','BG Menu Modal - Log In');\">Members Sign In</a></span>\n\t\t\t\t   \t\t</aside>\n\t   \t\t\t\t</div>\n\t   \t\t\t</div>\n   \t\t\t</nav>\n\n\n\n   \t<aside class=\"bg-header__pop-up\" aria-hidden=\"true\">\n   \t\t<div class=\"bg-header__close-pop-up js-close-pop-up\"></div>\n   \t\t<div class=\"bg-header__caret-wrapper\"><div class=\"bg-header__caret\"></div></div>\n   \t\t<section class=\"bg-header__pop-up-section bg-header__pop-up-section--digital\">\n   \t\t\t<img src=\"/img/masthead/lockup.png\" class=\"bg-header__sub-img\"/>\n   \t\t\t<p class=\"bg-header__sub-title\">Digital Access</p>\n   \t\t\t<p class=\"bg-header__promo-text\">99 cents a week for the first 4 weeks</p>\n\t\t    <a href=\"https://subscribe.bostonglobe.com/B3605/?eglobe_rc=WW20145D&p1=BGHeader_DigitalSubscription\" class=\"bg-header__sub-button bg-header__display-mobile\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG\tHeader Modal';s.events='event13';s.tl(this,'o','BG\tHeader\t\u2013 Subscribe\tDigital');\">Subscribe</a>\n\t\t\t<a href=\"https://subscribe.bostonglobe.com/B3605/?rc=WW20145D&eglobe_rc=WW20145D&p1=BGHeader_DigitalSubscription\" class=\"bg-header__sub-button bg-header__display-desktop\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG\tHeader Modal';s.events='event13';s.tl(this,'o','BG\tHeader\t\u2013 Subscribe\tDigital');\">Subscribe</a>\n\n   \t\t</section>\n   \t\t<section class=\"bg-header__pop-up-section bg-header__pop-up-section--delivery\">\n   \t\t\t<img src=\"/img/masthead/newspaper.png\" class=\"bg-header__sub-img\"/>\n   \t\t\t<p class=\"bg-header__sub-title\">Home Delivery</p>\n   \t\t\t<p class=\"bg-header__promo-text\">Save 50% off the regular rate</p>\n\t\t\t<a href=\"//homedelivery.bostonglobe.com/hd/26/order/zip/?rc=WW011964&globe_rc=WW011964&p1=BGHeader_HomeDeliverySubscription\" class=\"bg-header__sub-button bg-header__display-mobile\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG\tHeader Modal';s.events='event13';s.tl(this,'o','BG\tHeader\t\u2013 Subscribe\tHD');\">Subscribe</a>\n\t\t\t<a href=\"https://subscribe.bostonglobe.com/B0004/?rc=WW011964&globe_rc=WW011964&p1=BGHeader_HomeDeliverySubscription\" class=\"bg-header__sub-button bg-header__display-desktop\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar25,events';s.linkTrackEvents='event13';s.eVar25='BG\tHeader Modal';s.events='event13';s.tl(this,'o','BG\tHeader\t\u2013 Subscribe\tHD');\">Subscribe</a>\n   \t\t</section>\n   \t\t<span class=\"bg-header__sub-login\">Already a subscriber? <a href=\"/login?p1=BGHeader_Login_Link\" class=\"bg-header__sub-click\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='eVar27,events';s.linkTrackEvents='event15';s.eVar27='BG Header Modal';s.events='event15';s.tl(this,'o','BG Header Modal - Log In');\">Members Sign In</a></span>\n   \t</aside>\n\n</header>\n<!-- Page header ends -->\n\n<!-- story_default.jpt, story id:68804080-1364-11e7-8513-19a688a565f6 path:/Boston/2011-2020/2017/03/17/BostonGlobe.com/Business/Stories -->\n\n\t\t<div class=\"ad billboard\" id=\"ad_outofpage2\"></div>  <div class=\"ad billboard\" id=\"ad_billboard\"></div>  <div class=\"mod live-update\">\n\t\t\t</div>\n\n\t\t<main id=\"main\" role=\"main\" class=\"eptClick\">\n\t\t\t<article class=\"article\" itemscope=\"itemscope\"\n\t\t\t\titemtype=\"http://schema.org/NewsArticle\">\n\t\t\t\t<meta itemprop=\"inLanguage\" content=\"en-US\" />\n\t\t\t\t<meta itemprop=\"genre\" content=\"news\" />\n\t\t\t\t<meta itemprop=\"articleSection\" content=\"Business\" />\n\t\t\t\t<!-- Headline Section -->\n\t\t\t\t<header>\r\n\t<div class=\"header new\">\r\n\t<h1 class=\"main-hed\" itemprop=\"headline\">Hope for devastating child disease comes at a cost: $750,000 a year</h1>\r\n\t</div>\r\n\t\r\n\t</header>\r\n<div class=\"article-body\">\n\t\t\t\t\t<!-- position:Top -->\n<!--\nMETADATA FOR EMTAF\n      <headline>Hope for devastating child disease comes at a cost: $750,000 a year</headline>\n      <source>Globe Staff</source>\n      <teasetext>A new drug can treat children with a devastating disease, but it&amp;rsquo;s very expensive and insurers are balking at paying.  </teasetext>\n      <byline>By Robert Weisman</byline>\n      <date>20170328031238</date>\n-->\n\n<aside class=\"tools\">\n\t<ul class=\"Top tools primary-tools\">\n\t\t<!-- imgAltCaption: Newburyport, MA: 03-21-2017: Kernan Farrell (age 4, left and her brother Braeden Farrell (age 5) at their home in Newburyport, Mass. after Braeden arrived home from school March 21, 2017. He is retracting the wheelchair lift into his family's car. Both Braeden and Kernan have spinal muscular atrophy. Apparently Braeden gets the new Biogen drug Spinraza through a clinical trial, but Neighborhood Health Plan has denied coverage for Kernan. Photo/John Blanding, B oston Globe staff story/Robert Weisman, Business, ( 22spinraza ) -->\n\t\t<li class=\"email\">\n\t      <a class=\"bg-button--email email\" onClick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','ArticleTools_Email_Top');\" data-omniture=\"BG Article Share Tools - Email - Top\" target=\"_blank\" title=\"Share via E-mail\" aria-label=\"Share via E-mail\" href=\"#\"><span class=\"bg-icon--email\">E-Mail</span></a>\n\t      <div class=\"email-form\">\n\t\t\t\t<h4>Share via e-mail</h4>\n\t\t\t\t<div class=\"email-error\"></div>\n\t\t\t\t<form action=\"\" method=\"post\">\n\t\t\t\t\t<input type=\"hidden\" id=\"story_url-Top\" name=\"story_url\" value=\"http://www.bostonglobe.com/business/2017/03/27/spinraza/QnBmQrcmLLfUwvJunn0P8K/story.html\"/>\n\t\t\t\t\t<p>\n\t\t\t\t\t\t<label for=\"email-to-primary-Top\">To</label>\n\t\t\t\t\t\t<input type=\"text\" name=\"email-to-primary\" id=\"email-to-primary-Top\" placeholder=\"Separate multiple addresses with a comma\" />\n\t\t\t\t\t</p>\n\t\t\t\t\t<p>\n\t\t\t\t\t\t<label for=\"email-mssg-primary-Top\">Add a message</label>\n\t\t\t\t\t\t<textarea name=\"email-mssg-primary\" id=\"email-mssg-primary-Top\" maxlength=\"80\" placeholder=\"80 character limit\"></textarea>\n\t\t\t\t\t</p>\n\t\t\t\t\t<p>\n\t\t\t\t\t\t<label for=\"email-from-primary-Top\">Your e-mail</label>\n\t\t\t\t\t\t<input type=\"text\" name=\"email-from-primary\" id=\"email-from-primary-Top\" />\n\t\t\t\t\t</p>\n\t\t\t\t\t<input type=\"submit\" value=\"Send\" class=\"bg-button\" onClick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','ArticleTools_Send_Top');\"/>\n\t\t\t\t</form>\n\t\t\t</div><!-- /end .email-form -->\n\t    </li>\n\t    <li>\n\t      <a class=\"bg-button--fb\" data-omniture=\"BG Article Share Tools - Facebook - Top\" href=\"http://www.facebook.com/sharer.php?u=http%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F03%2F27%2Fspinraza%2FQnBmQrcmLLfUwvJunn0P8K%2Fstory.html%3Fevent%3Devent25&amp;t=Hope for devastating child disease comes at a cost: $750,000 a year\" target=\"_blank\" title=\"Share on Facebook\" aria-label=\"Share on Facebook\"><span class=\"bg-icon--fb\">Facebook</span></a>\n\t    </li>\n\t    <li>\n\t      <a class=\"bg-button--twitter\" data-omniture=\"BG Article Share Tools - Twitter - Top\" href=\"http://twitter.com/intent/tweet?text=Hope for devastating child disease comes at a cost: $750,000 a year&amp;url=http%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F03%2F27%2Fspinraza%2FQnBmQrcmLLfUwvJunn0P8K%2Fstory.html%3Fevent%3Devent25&amp;via=BostonGlobe\" target=\"_blank\" title=\"Share on Twitter\" aria-label=\"Share on Twitter\"><span class=\"bg-icon--twitter\">Twitter</span></a>\n\t    </li>\n\t    <li>\n\t\t\t<a class=\"bg-button--gplus\" data-omniture=\"BG Article Share Tools - Google+ - Top\" href=\"https://plus.google.com/share?url=http%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F03%2F27%2Fspinraza%2FQnBmQrcmLLfUwvJunn0P8K%2Fstory.html%3Fevent%3Devent25%26s_campaign%3dsm_gp%26hl=en-US\" target=\"_blank\" title=\"Share on Google+\" aria-label=\"Share on Google+\"><span class=\"bg-icon--gplus\">Google+</span></a>\n\t\t\t\t</li>\n\t    <li>\n\t      <a class=\"bg-button--linkedin\" data-omniture=\"BG Article Share Tools - Linkedin - Top\" href=\"http://www.linkedin.com/shareArticle?mini=true&amp;url=http%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F03%2F27%2Fspinraza%2FQnBmQrcmLLfUwvJunn0P8K%2Fstory.html%3Fevent%3Devent25&amp;title=Hope for devastating child disease comes at a cost: $750,000 a year&amp;summary=A+new+drug+can+treat+children+with+a+devastating+disease%2C+but+it%26amp%3Brsquo%3Bs+very+expensive+and+insurers+are+balking+at+paying.++\" target=\"_blank\" title=\"Share on LinkedIn\" aria-label=\"Share on LinkedIn\"><span class=\"bg-icon--linkedin\">LinkedIn</span></a>\n\t    </li>\n\t</ul>\n\t<a href=\"#comments\" class=\"js-comments-toggle bg-button--generic\">\n\t\t  <span class=\"bg-icon-comment-dark bg-icon--small\"></span>\n\t\t  <span class=\"js-comment-count\"></span> <span class=\"js-comment-count-label bg-visuallyhidden\">Comments</span>\n\t\t</a>\n\n\t<a class=\"bg-button--generic bg-button--print\" onclick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','ArticleTools_Print_Top')\" href=\"javascript:print();\">\n\t\t\t<span class=\"bg-icon--print bg-icon--small\"></span>\n\t\t\t<span class=\"bg-visuallyhidden\">Print</span></a>\n\t\t</aside>\n<div class=\"sticky-tools\">\n\t\t<a class=\"sticky-tools__button sticky-tools__button--home\" href=\"/?p1=BGHeader_Logo_Sticky\">\n\t\t    <span>The Boston Globe</span>\n\t\t</a><a class=\"sticky-tools__button sticky-tools__button--share tw\" data-omniture=\"BG Article Share Tools - Twitter - Sticky\" href=\"http://twitter.com/intent/tweet?text=Hope for devastating child disease comes at a cost: $750,000 a year&amp;url=http%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F03%2F27%2Fspinraza%2FQnBmQrcmLLfUwvJunn0P8K%2Fstory.html%3Fevent%3Devent25%3Fevent%3Devent25&amp;via=BostonGlobe\" target=\"_blank\" title=\"Share on Twitter\">\n\t\t    <span>Tweet</span>\n\t\t</a><a class=\"sticky-tools__button sticky-tools__button--share fb\" data-omniture=\"BG Article Share Tools - Facebook - Sticky\" href=\"http://www.facebook.com/sharer.php?u=http%3A%2F%2Fwww.bostonglobe.com%2Fbusiness%2F2017%2F03%2F27%2Fspinraza%2FQnBmQrcmLLfUwvJunn0P8K%2Fstory.html%3Fevent%3Devent25%3Fevent%3Devent25&amp;tHope for devastating child disease comes at a cost: $750,000 a year\" target=\"_blank\" title=\"Share on Facebook\">\n\t\t    <span>Share</span>\n\t\t</a><a class=\"sticky-tools__button sticky-tools__button--share sticky-comments js-sticky-comments\" href=\"#comments\">\n\t\t    <span></span>\n\t\t    <p class=\"js-comment-count sticky-comments-count\"></p>\n\t\t    <p class=\"js-comment-count-label sticky-comments-count-label\"></p>\n\t\t</a>\n\t\t<div class=\"sticky-tools__button sticky-tools__button--top js-back-to-top\"></div>\n\t</div>\n<!-- Header Tabs Section -->\n\t\t\t\t\t<figure itemprop=\"associatedMedia\" itemscope itemtype=\"http://schema.org/ImageObject\" class=\"figure lead-figure full\">\n\t\t<img  itemprop=\"contentUrl\" src=\"//www.bostonglobe.com/rf/image_r/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza5biz.r.jpg\" data-fullsrc=\"//c.o0bg.com/rf/image_960w/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza5biz.jpg\" alt=\"Newburyport, MA: 03-21-2017: Kernan Farrell (age 4, left and her brother Braeden Farrell (age 5) at their home in Newburyport, Mass. after Braeden arrived home from school March 21, 2017. He is retracting the wheelchair lift into his family&apos;s car. Both Braeden and Kernan have spinal muscular atrophy. Apparently Braeden gets the new Biogen drug Spinraza through a clinical trial, but Neighborhood Health Plan has denied coverage for Kernan. Photo/John Blanding, B oston Globe staff story/Robert Weisman, Business, ( 22spinraza )\"/>\n\t\t<figcaption class=\"figcaption\">\n\t\t\t<meta itemprop=\"creator\" content=\"John Blanding\" />\n\t\t\t<p class=\"credit\">John Blanding/Globe staff</p>\n\t\t\t<p itemprop=\"description caption\">Braeden Farrell, 5,  operated a wheelchair lift at his family&#8217;s home in Newburyport. Both he and his sister, Kernan, 4, have spinal muscular atrophy.</p>\n\t\t</figcaption>\n\t</figure>\t\n<div class=\"byline\">\r\n\t<b class=\"author\"><!---->By <a class=\"\" title=\"More Stories by Robert Weisman\" href=\"/staff/weisman\" rel=\"author\"><span itemprop=\"name\">Robert Weisman</span></a></b>\r\n\tGlobe Staff&nbsp;\r\n\t<time itemprop=\"datePublished\" datetime=\"2017-03-28 03:12\">March 28, 2017</time>\r\n\t<p></p>\r\n\t<p></p>\r\n</div><div class=\"article-text\" itemprop=\"articleBody\">\n\t\t\t\t\t\t<!-- leading video or graphic -->\n\t\t\t\t\t\t<!-- inside story_update.jpt -->\n<!-- In Story Photo or Graphic Section -->\n\t\t\t\t\t\t\t<!-- paragraphs 31 leadingContainer photo\n\t\t\t\t\t\t\t\t\t\tleadingShape horizontal hasRBox false -->\n\t\t\t\t\t\t\t\t\t<!----><p>Parents of children with a rare disease called <a class=\"a\" href=\"https://www.mda.org/disease/spinal-muscular-atrophy?gclid=CIzgxZC279ICFY2LswodnqUCSA\" shape=\"rect\">spinal muscular atrophy</a> were thrilled two days before Christmas, when regulators <a class=\"a\" href=\"https://www.bostonglobe.com/business/2016/12/23/biogen-gets-fda-approval-for-first-spinal-muscular-atrophy-treatment/PdhHD9XpnDpfk428JhEYBN/story.html\" shape=\"rect\">approved</a> the first drug to treat the condition that often kills patients before their second birthday.</p><p>But in the three months since, some parents in Massachusetts have fought to get their insurer, <a class=\"a\" href=\"https://www.nhp.org/Pages/Home.aspx\" shape=\"rect\">Neighborhood Health Plan,</a> to pay for the medicine, an enormously expensive drug called Spinraza and made by Cambridge-based <a class=\"a\" href=\"https://www.biogen.com/\" shape=\"rect\">Biogen Inc</a>.</p><p class=\"skip-nav article-more\">\n\t<a>Advertisement</a>\n\t</p>\n\n<div class=\"ad aside\" id=\"ad_bigbox1\"></div>  <a id=\"skip-target1\"></a>\n\n<p>The drug&rsquo;s list price of $750,000 for the first year, and $375,000 annually after that, makes it one of the costliest medicines on the market.</p><p>Last week, the parents of a Newburyport girl won a ruling that orders coverage for the drug &mdash; but it appears to be a decision that only applies to their case.</p><div class=\"inline-newsletter\" data-exact-target-ID=\"20712964\" data-mailing-list-name=\"Talking Points\" data-is-amp=\"\" data-section=\"\">\n  <div class=\"inline-newsletter__network-error\"></div>\n  <div class=\"inline-newsletter__copy\">\n    <div class=\"inline-newsletter__title\">\n      Get <span class=\"inline-newsletter__bold\">Talking Points</span> in your inbox:\n    </div>\n    <div class=\"inline-newsletter__description\">\n        An afternoon recap of the day\u2019s most important business news, delivered weekdays.</div>\n    </div>\n  <form class=\"inline-newsletter__content\" method=\"post\">\n    <div class=\"inline-newsletter__error-text\"></div>\n    <input placeholder=\"Enter email address\" type=\"text\" id=\"inline-newsletter-email-input\" class=\"inline-newsletter__input\">\n    \n    <div class=\"inline-newsletter__button-container\">\n      <button class=\"inline-newsletter__button\">\n        <span class=\"inline-newsletter__button-text\">Sign Up</span>\n      </button>\n      <div class=\"inline-newsletter__spinner\"></div>\n    </div>\n  </form>\n  <div class=\"inline-newsletter__thanks\">\n    Thank you for signing up! \n    <a href=\"/newsletters?p1=Article_inline-newsletterWidget_ThankYou_Link\" class=\"inline-newsletter__link\">Sign up for more newsletters here</a>\n    </div>\n</div>\n\n<p>The jockeying over reimbursement for Spinraza has become a familiar scenario in the world of breakthrough drugs, reflecting a gulf between patients&rsquo; hopes and business realities.</p><!-- total:0 -->\n\n<p>Insurers are demanding stronger evidence to justify the prices of these sorts of drugs. Recently, for example, some have balked at paying for a new drug that prevents strokes and another that treats Duchenne muscular dystrophy. Historically, insurers have usually covered the cost of new medicines for rare diseases with no other treatments.</p><p>Drug makers contend that their high prices are justified by the many millions of dollars they sink into research and testing on experimental medicines, many of which never make it to clinical trials.</p><!--  working ad -->\n<p class=\"skip-nav article-more\">\n\t<a>Advertisement</a>\n\t<!-- <a href=\"#skip-target2\">Continue reading below</a> -->\n</p>\n<!-- adLayerPath: /Boston/Production/BostonGlobe.com/WebPages/Homepage/homepage.ad-layer.story-asset.dwp -->\n<div class=\"ad aside\" id=\"ad_bigbox2\"></div>  <a id=\"skip-target2\"></a>\n\n<p>In the case of Spinraza, a state patient protection panel ruled this month that Neighborhood Health was wrong to deny coverage to Kernan Farrell, 4, of Newburyport, who is suffering from a less-critical type of the condition. Her parents, Kristen and Jim Farrell, turned to the <a class=\"a\" href=\"http://www.mass.gov/anf/budget-taxes-and-procurement/oversight-agencies/health-policy-commission/\" shape=\"rect\">Health Policy Commission</a> after losing an in-house appeal to Neighborhood Health.</p><figure class=\"figure\" itemtype=\"http://schema.org/ImageObject\" itemprop=\"associatedMedia\">\n<img alt=\"Newburyport, MA: 03-21-2017: (l-r) Kristen Farrell, Kernan Farrell (age 4), Braeden Farrell (age 5) and Jim Farrell at their home in Newburyport, Mass. March 21, 2017. Both Braeden and Kernan have spinal muscular atrophy. Apparently Braeden gets the new Biogen drug Spinraza through a clinical trial, but Neighborhood Health Plan has denied coverage for Kernan. Photo/John Blanding, Boston Globe staff story/Robert Weisman, Business, ( 22spinraza )\" data-fullsrc=\"//c.o0bg.com/rf/image_460w/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza2biz.jpg\" src=\"//c.o0bg.com/rf/image_r/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza2biz.r.jpg\" itemprop=\"url\"><figcaption class=\"figcaption\">\n<p class=\"credit\">John Blanding/Globe Staff</p>\n<p>Kristen Farrell, Kernan Farrell, Braeden Farrell, and Jim Farrell at their home in Newburyport.</p>\n</figcaption>\n</figure><p>Neighborhood Health must comply with the decision, said Matthew Kitsos, a spokesman for the commission, but it doesn&rsquo;t set a precedent; appeals for coverage from other patients with spinal muscular atrophy, known as SMA, will be considered individually.</p><p>Neighborhood Health said it will only cover patients with the most severe form of the disease, until it gets more data about how well the drug works.</p><p>Meantime, the insurer continues to reject coverage for patients with less severe forms of the condition, which destroys the muscles of more than 10,000 children in the United States.</p><p>Neighborhood Health Plan, which lost more than $100 million last year, said it bases its decisions on Spinraza cases purely on medical criteria. The insurer, which is owned by Partners HealthCare, the largest health network in the state, said it will reassess its position as new information about the injectable drug becomes available.</p><p>That means other families are still scrambling to figure out how, or whether, they&rsquo;ll get access to the new treatment, prescribed by neurologists at Boston Children&rsquo;s Hospital and other medical centers.</p><p>SMA disables the nerve signals controlling muscle movement. In clinical trials, Spinraza helped children stricken with SMA to hold up their heads, sit up, stand on their own, and walk short distances.</p><p>&ldquo;This is something that could help our son Tyler,&rdquo; said Boston consultant Doug Hansen, who last week learned he had lost his appeal to Neighborhood Health of its denial of Spinraza coverage for his 11-year-old. &ldquo;It could stop or dramatically reduce the progression of the disease.&rdquo;</p><p>Tyler was diagnosed with SMA in 2015 after his parents noticed he was falling several times a day. &ldquo;He would just drop,&rdquo; said his mother, Kim. &ldquo;It was like his legs would give out.&rdquo;</p><p>Doug Hansen said he, like the Farrells did, will bring his case to the Health Policy Commission unless the insurer changes its decision.</p><p>\n<b class=\"b\"></b>\nNavigating the bureaucracy around SMA treatments has become a necessary practice for such families as the Farrells. <b class=\"b\"></b>In addition to Kernan, their 5-year-old son, Braeden, also has the condition. Kristen Farrell said that before her children were diagnosed, she had never heard of the disease.</p><p>Braeden, who was diagnosed when he was 15 months old, walks with a brace but typically moves about in a wheelchair powered by a small motor. He has been able to receive spinal injections of Spinraza through a clinical trial at Boston Children&rsquo;s since he was 2&frac12; years old, and it has helped him hold up his head, open a cup lid, and hug his parents. His sister Kernan, diagnosed three weeks after she was born, is still walking but has difficulty balancing and falls frequently.</p><div class=\"wide\">\n<img alt=\"Boston, MA - 3/20/2017 - Tyler Hansen, who suffers from spinal muscular atrophy, wrestles with his father Doug at their home in Boston, MA, March 20, 2017. Neighborhood Health Plan is denying coverage for the new Biogen drug Spinraza to some MA children suffering from spinal muscular atrophy. The drug costs as much as $750,000 in the first year. (Keith Bedford/Globe Staff)\" data-fullsrc=\"//c.o0bg.com/rf/image_1920w/Boston/2011-2020/2017/03/21/BostonGlobe.com/Business/Images/Bedford_170320_SPINAL_ATROPHY_016.jpg\" src=\"//c.o0bg.com/rf/image_r/Boston/2011-2020/2017/03/21/BostonGlobe.com/Business/Images/Bedford_170320_SPINAL_ATROPHY_016.r.jpg\"><div class=\"figcaption\">\n<p class=\"credit\">Keith Bedford/Globe Staff</p>\n<p>Tyler Hansen, who suffers from spinal muscular atrophy, wrestled with his father Doug at their home in Boston.</p>\n</div>\n</div><p>Neighborhood Health declined to make executives available for an interview, but in a statement the insurer said it considers only evidence of &ldquo;safety and efficacy&rdquo; when ruling on what drugs to cover for which patients.</p><p>It offered a partial explanation for the distinctions it draws in denial letters to the families.</p><p>\n<b class=\"b\"></b>The insurer&rsquo;s drug review panel determined that Biogen had demonstrated Spinraza&rsquo;s effectiveness only for Type 1 SMA patients &mdash; those most severely affected. In its denial letters, Neighborhood Health said Type 3 &mdash; the form that Tyler Hansen and Kernan Farrell have &mdash; wasn&rsquo;t the focus of Biogen&rsquo;s study of the drug. It said the clinical data its panel reviewed &ldquo;does not meet our medical necessity criteria&rdquo; for Type 3, which typically affects children who learn to stand and walk, but eventually lose that ability.</p><p>But when it approved the drug for US sales on Dec. 23, the Food and Drug Administration specified it was approved for all children with SMA. Biogen, in fact, submitted clinical data to the agency showing the drug&rsquo;s effectiveness in children with less severe forms of the disease, though its tests didn&rsquo;t compare those patients with others taking a placebo, as they did with Type 1 patients. It is continuing to test the drug on later-onset patients.</p><p>The health plan&rsquo;s policy is &ldquo;just not right,&rdquo; said Kristen Farrell, a sign language interpreter. &ldquo;We feel lucky there&rsquo;s a treatment now, and there&rsquo;s good science behind it.&rdquo;</p><figure class=\"figure\" itemtype=\"http://schema.org/ImageObject\" itemprop=\"associatedMedia\">\n<img alt=\"Boston, MA - 3/20/2017 - Tyler Hansen, who suffers from spinal muscular atrophy, stands in the hallway of the family home in Boston, MA, March 20, 2017. Neighborhood Health Plan is denying coverage for the new Biogen drug Spinraza to some MA children suffering from spinal muscular atrophy. The drug costs as much as $750,000 in the first year. (Keith Bedford/Globe Staff)\" data-fullsrc=\"//c.o0bg.com/rf/image_371w/Boston/2011-2020/2017/03/21/BostonGlobe.com/Business/Images/Bedford_170320_SPINAL_ATROPHY_021.jpg\" src=\"//c.o0bg.com/rf/image_r/Boston/2011-2020/2017/03/21/BostonGlobe.com/Business/Images/Bedford_170320_SPINAL_ATROPHY_021.r.jpg\" itemprop=\"url\"><figcaption class=\"figcaption\">\n<p class=\"credit\">Keith Bedford/Globe Staff</p>\n<p>Tyler Hansen.</p>\n</figcaption>\n</figure><p>In its statement, Neighborhood Health said it could not discuss specific cases because of privacy concerns. It said the insurer&rsquo;s pharmacy and therapeutics committee, staffed by independent doctors and pharmacists, followed a &ldquo;rigorous process&rdquo; in concluding it should cover Spinraza only for Type 1 patients.</p><p>Dr. Basil Darris, director of the SMA program at Boston Children&rsquo;s, who ran the hospital&rsquo;s clinical trials of Spinraza, said the existing data are strong enough for him to prescribe the drug for all patients with the disease.</p><p>&ldquo;We&rsquo;re happy that we now have a drug for these patients, and we can see the benefits,&rdquo; Darris said. &ldquo;There&rsquo;s an urgency here.&rdquo;</p><p>While insurers have stepped up their criticism of high drug prices, many &mdash; including Aetna and United HealthGroup, two of the nation&rsquo;s biggest carriers &mdash; are covering Spinraza for all patients. Biogen chief executive Michel Vounatsos told a health care conference earlier this month that more than 50 regional and national health plans will pay for the drug. Other insurers, including about 20 Medicaid plans nationally, are evaluating Spinraza claims case by case.</p><p>That&rsquo;s the approach the three largest Massachusetts health insurers &mdash; Blue Cross and Blue Shield, Harvard Pilgrim, and Tufts Health Plan &mdash; are taking for now. All five Blue Cross members in Massachusetts who requested Spinraza &mdash; including some Type 3 patients &mdash; were approved for coverage, said senior vice president Jay McQuaide.</p><p>Biogen spokesman Todd Cooper said the cost of Spinraza is &ldquo;in line with what we&rsquo;ve seen in other orphan therapies&rdquo; &mdash; new drugs that treat rare genetic diseases for which there are no other treatments. The company subsidizes the cost to qualified patients who don&rsquo;t have insurance, but the subsidies don&rsquo;t cover the steep cost of the injection procedure itself.</p><!----><p></p><i>Robert Weisman can be reached at <a class=\"a\" href=\"mailto:robert.weisman@globe.com\">robert.weisman@globe.com</a>. Follow him on Twitter <a class=\"a\" href=\"http://twitter.com/GlobeRobW\">@GlobeRobW</a>.</i><!-- inside story_update.jpt -->\n</div><!-- end article-text -->\n\t\t\t\t\t<!-- Story tools -->\n\t\t\t\t\t\t<!-- for comments -->\n\t\t\t\t\t<footer class=\"article-footer\" role=\"contentinfo\">\n<script>var uuid = '68804080-1364-11e7-8513-19a688a565f6';</script>\n<div id=\"comments\">\n\t<div id=\"comments-content\" class=\"ugc-comments comments\">\n\t\t<div class=\"loading-message\" id=\"loading-comments\">\n\t\t\tLoading comments...\n\t\t\t </div>\n\t</div>\n</div>\n<div id=\"newcomments\"></div>\n</footer>\n</div><!-- ends article-body -->\n\t\t\t\t<!-- place for ads and trending -->\n\t\t\t\t<nav id=\"section-nav\" class=\"section-nav trending-nav\" data-sectionname=\"/business\">\n     <h3>Top 10 Trending Articles</h3>\n      <nav>\n        <ul class=\"bg-tabs-sidebar bg-33-33-33\">\n          <li><a class=\"here js-show-tab\" href=\"#most-viewed\">Most Viewed</a></li>\n          <li><a class=\"js-show-tab\" href=\"#most-commented\">Most Commented</a></li>\n          <li><a class=\"js-show-tab\" href=\"#most-shared\">Most Shared</a></li>\n        </ul>\n      </nav>\n\n      </nav>\n</article>\n\t\t</main>\n\t\t<!-- Page footer -->\n<a href=\"http://subscribe.bostonglobe.com/B0565?p1=BGFooter_DigitalSubscription_Banner\">\n<div class=\"subscription-banner\">\n\t<span class=\"subscription-banner__title\">Real journalists. Real journalism. </span>\n\t<span class=\"subscription-banner__link\" >Subscribe to The Boston Globe today.</span>\n</div>\n</a><footer class=\"site-footer\" role=\"contentinfo\">\n\t<div class=\"site-footer__content\">\n\t\t<ul class=\"site-footer__list\">\n\t\t\t<li class=\"site-footer__list-item\"><h3 class=\"site-footer__heading\">My Account</h3></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://www.bostonglobe.com/login?p1=BGFooter\" class=\"site-footer__link\">Log in</a></li>\n\t<li class=\"site-footer__list-item\"><a href=\"https://manage.bostonglobe.com/cs/mc/login.aspx?p1=BGFooter\" class=\"site-footer__link\">Manage my Account</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://www.bostonglobe.com/bgcs\" class=\"site-footer__link\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Footer - Download Customer Service App');\">Mobile Customer Service</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"/newsletters?p1=BGFooter_Newsletters\" class=\"site-footer__link\">Sign Up For Newsletters</a></li>\n\t\t</ul>\n\n\t\t<ul class=\"site-footer__list\">\n\t\t\t<li class=\"site-footer__list-item\"><h3 class=\"site-footer__heading\">Contact</h3></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://bostonglobe.custhelp.com/app/home?p1=BGFooter\" class=\"site-footer__link\">Help</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://bostonglobe.custhelp.com/app/answers/list?p1=BGFooter\" class=\"site-footer__link\">FAQs</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"/tools/help/stafflist?p1=BGFooter\" class=\"site-footer__link\">Globe newsroom</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://www.bostonglobemedia.com/\" class=\"site-footer__link\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Footer - BGM Home Page');\">Advertise</a></li>\n\t\t</ul>\n\n\t\t<ul class=\"site-footer__list\">\n\t\t\t<li class=\"site-footer__list-item\"><h3 class=\"site-footer__heading\">Social</h3></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://www.facebook.com/globe\" class=\"site-footer__link\">Facebook</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://twitter.com/#!/BostonGlobe\" class=\"site-footer__link\">Twitter</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://plus.google.com/108227564341535363126/about\" class=\"site-footer__link\">Google+</a></li>\n\t\t</ul>\n\n\t\t<ul class=\"site-footer__list\">\n\t\t\t<li class=\"site-footer__list-item\"><h3 class=\"site-footer__heading\">More</h3></li>\n\t\t    <li class=\"site-footer__list-item\"><a href=\"http://epaper.bostonglobe.com/launch.aspx?pbid=2c60291d-c20c-4780-9829-b3d9a12687cf\" class=\"site-footer__link\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Footer - EPaper launch');\">ePaper</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"http://nieonline.com/bostonglobe/\" class=\"site-footer__link\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Footer - News In Education');\">News in Education</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://secure.pqarchiver.com/boston-sub/no_default.html?ss=1&amp;url=%2Fboston-sub%2Fadvancedsearch.html\" class=\"site-footer__link\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Footer - Public Archives');\">Archives</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"/tools/help/privacy?p1=BGFooter\" class=\"site-footer__link\">Privacy policy</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"/tools/help/terms-service?p1=BGFooter\" class=\"site-footer__link\">Terms of service</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"/termsofpurchase?p1=BGFooter\" class=\"site-footer__link\">Terms of purchase</a></li>\n\t\t\t<li class=\"site-footer__list-item\"><a href=\"https://www.bostonglobemedia.com/careers\" class=\"site-footer__link\" onclick=\"var s=s_gi('nytbostonglobecom');s.linkTrackVars='channel,prop1,eVar15';s.linkTrackEvents='none';s.tl(this,'o','BG Footer - BGM Careers');\">Work at Boston Globe Media</a></li>\n\t\t</ul>\n\t\t<p class=\"site-footer__copyright\">&copy; 2017 Boston Globe Media Partners, LLC</p>\n\t</div>\n</footer>\n\n<script type=\"text/javascript\" src=\"//tags.mediaforge.com/js/4600\"></script>\n\n<script type=\"text/javascript\">\n\tvar google_conversion_id = 1071256246;\n\tvar google_custom_params = window.google_tag_params;\n\tvar google_remarketing_only = true;\n</script>\n<script type=\"text/javascript\" src=\"//www.googleadservices.com/pagead/conversion.js\" ></script>\n<noscript>\n\t<div style=\"display:inline;\">\n\t\t<img height=\"1\" width=\"1\" style=\"border-style:none;\" alt=\"\" src=\"//googleads.g.doubleclick.net/pagead/viewthroughconversion/1071256246/?value=0&amp;guid=ON&amp;script=0\"/>\n\t</div>\n</noscript>\n\n<script>\n\n\t$(document).ready(function(){\n\n\t\t getScriptCached('//connect.facebook.net/en_US/sdk.js').done(function() {\n\t\t  FB.init({\n\t\t    appId      : '751395421611272',\n\t\t    cookie     : true,  // enable cookies to allow the server to access\n\t\t    xfbml      : true,  // parse social plugins on this page\n\t\t    version    : 'v2.2' // use version 2.2\n\t\t  });\n\n\t\t  FB.getLoginStatus(function(response) {\n\t\t    statusChangeCallback(response);\n\t\t  });\n\t  });\n\n\t});\n  function testAPI() {\n    // console.log('Welcome!  Fetching your information.... ');\n    FB.api('/me', function(response) {\n      // console.log('Successful login for: ' + response.name);\n\n      var fbObject = {};\n      fbObject.email = response.email;\n      fbObject.firstName = response.first_name;\n      fbObject.lastName = response.last_name;\n\n\t\t\tif(response.gender === undefined){\n\t\t\t\t// console.log('Gender is custom or undefined');\n\t\t\t}else{\n      fbObject.gender = ( response.gender == \"male\" ) ? 'M' : 'F';\n\t\t\t}\n      // console.log(response);\n      // console.log(fbObject);\n\t  bglobe.social.sendEmail(fbObject);\n    });\n  }\n  function statusChangeCallback(response) {\n    // console.log('statusChangeCallback');\n    // console.log(response);\n    if (response.status === 'connected') {\n      // console.log('Successful login');\n    } else if (response.status === 'not_authorized') {\n      //  console.log('The person is logged into Facebook, but not your app');\n    } else {\n      //  console.log('The person is not logged into Facebook');\n    }\n  }\n\n  function checkLoginState() {\n    FB.getLoginStatus(function(response) {\n      statusChangeCallback(response);\n    });\n  }\n  function fblogin(){\n\t  FB.login(function(response){\n\t\t  if(response.authResponse){\n\t\t\t  // console.log('connected');\n\t\t\t  testAPI();\n\t\t  }else{\n\t\t  // console.log('User response not authorized');\n\t\t  }\n\t  },{scope:\"public_profile,email\"});\n  }\n  function getScriptCached(url, ajaxOpts){\n\t  ajaxOpts = $.extend( ajaxOpts || {} , {dataType: \"script\", cache: true, url: url});\n\t  return jQuery.ajax( ajaxOpts );\n  }\n</script>\n\n\n<div style=\"display:none;\">\n<!--  infinite meter AGAIN !@)$&!()!!! -->\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-old-one-animation\">\n\t<div class=\"infinite-modal__black-bar infinite-modal__black-bar-one\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\t\t\t<table>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<div class=\"infinite-modal__one-one\">\n\t\t\t\t<div class=\"infinite-modal__big-logo\"></div>\n\t\t\t\t<div class=\"infinite-modal__one-headline\">\n\t\t\t\t\tYou're reading&nbsp;<span class=\"infinite-modal__hilite-text\">&nbsp;1 of 5 free articles.</span>\n\t\t\t\t</div>\n\t\t\t\t<div class=\"infinite-modal__one-secondline\"><span class=\"infinite-modal__mobile-supression infinite-modal__grey-text\">Get UNLIMITED access for only 99\u00a2 per week</span> Subscribe Now ></div>\n\t\t\t</div>\n\t\t\t<div class=\"infinite-modal__one-two\">\n\t\t\t\t<div class=\"infinite-modal__logo\"></div>\n\t\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t\tYou're reading<span class=\"infinite-modal__hilite-text\">1 of 5 free articles.</span><span class=\"infinite-modal__mobile-supression\"><span class=\"infinite-modal__grey-text\">Keep scrolling to see more articles recomended for you</span> Subscribe now  </span>\n\t\t\t\t</div>\n\t\t\t</div>\n\t\t</div>\n\t</div>\n</div>\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-one\">\n\t<a href=\"#\" onclick=\"trackPaywallSubscribe(1); return false;\">\n\t<div class=\"infinite-modal__black-bar infinite-modal__first-animation\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\t\t\t<table>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<div class=\"infinite-modal__logo infinite-modal__mobile-supression\"></div>\n\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t<span class=\"infinite-modal__mobile-supression\">You're reading</span> <span class=\"infinite-modal__hilite-text\">1 of 5 </span>free articles. <span class=\"infinite-modal__grey-text infinite-modal__mobile-supression\"> Get UNLIMITED access for only 99\u00a2 per week. </span>Subscribe now\n\t\t\t</div>\n\t\t</div>\n\t</div>\n\t</a>\n</div>\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-two\">\n\t<a href=\"#\" onclick=\"trackPaywallSubscribe(2); return false;\">\n\t<div class=\"infinite-modal__black-bar\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\t\t\t<table>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<div class=\"infinite-modal__logo infinite-modal__mobile-supression\"></div>\n\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t<span class=\"infinite-modal__mobile-supression\">You're reading</span> <span class=\"infinite-modal__hilite-text\">2 of 5 </span>free articles. <span class=\"infinite-modal__grey-text infinite-modal__mobile-supression\"> Get UNLIMITED access for only 99\u00a2 per week. </span>Subscribe now\n\t\t\t</div>\n\t\t</div>\n\t</div>\n\t</a>\n</div>\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-three\">\n\t<a href=\"#\" onclick=\"trackPaywallSubscribe(3); return false;\">\n\t<div class=\"infinite-modal__black-bar\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\t\t\t<table>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<div class=\"infinite-modal__logo infinite-modal__mobile-supression\"></div>\n\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t<span class=\"infinite-modal__mobile-supression\">You're reading</span> <span class=\"infinite-modal__hilite-text\">3 of 5 </span>free articles. <span class=\"infinite-modal__grey-text infinite-modal__mobile-supression\"> Get UNLIMITED access for only 99\u00a2 per week. </span>Subscribe now\n\t\t\t</div>\n\t\t</div>\n\t</div>\n\t</a>\n</div>\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-four\">\n\t<a href=\"#\" onclick=\"trackPaywallSubscribe(4); return false;\">\n\t<div class=\"infinite-modal__black-bar\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\t\t\t<table>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td></td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<div class=\"infinite-modal__logo infinite-modal__mobile-supression\"></div>\n\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t<span class=\"infinite-modal__mobile-supression\">You're reading</span> <span class=\"infinite-modal__hilite-text\">4 of 5 </span>free articles. <span class=\"infinite-modal__grey-text infinite-modal__mobile-supression\"> Get UNLIMITED access for only 99\u00a2 per week. </span>Subscribe now\n\t\t\t</div>\n\t\t</div>\n\t</div>\n\t</a>\n</div>\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-five\">\n\t<a href=\"#\" onclick=\"trackPaywallSubscribe(5); return false;\">\n\t<div class=\"infinite-modal__black-bar\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\t\t\t<table>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t\t<td class=\"used-article\"></td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<div class=\"infinite-modal__logo infinite-modal__mobile-supression\"></div>\n\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t<span class=\"infinite-modal__mobile-supression\">You're reading</span> <span class=\"infinite-modal__hilite-text\">5 of 5 </span>free articles. <span class=\"infinite-modal__grey-text infinite-modal__mobile-supression\"> Get UNLIMITED access for only 99\u00a2 per week. </span>Subscribe now\n\t\t\t</div>\n\t\t</div>\n\t</div>\n\t</a>\n</div>\n\n<div class=\"bg-modal__bottom-modal\" id=\"infinite-paywall\">\n\t<div class=\"infinite-modal__black-bar infinite-modal__black-bar-paywall\">\n\t\t<div class=\"infinite-modal__wrapper\">\n\n\t\t\t<div class=\"infinite-modal__text-holder\">\n\t\t\t\t<div class=\"infinite-modal__paywall-one\">\n\t\t\t\t\tWe hope you've enjoyed your 5 free articles.\n\t\t\t\t</div>\n\t\t\t\t<div class=\"infinite-modal__paywall-two\">\n\t\t\t\t\tContinue reading by subscribing to Globe.com for just 99\u00a2.\n\t\t\t\t</div>\n\t\t\t\t<div class=\"infinite-modal__paywall-three\">\n\t\t\t\t\t<a href=\"#\" class=\"infinite-modal__subscribe\" onclick=\"trackPaywallSubscribe('paywall');\">Subscribe Now</a>&nbsp;Already a member? <a class=\"infinite-modal__link\" href=\"https://www.bostonglobe.com/login\" onclick=\"trackPaywallSubscribe('paywall-login');\" >Log in</a>&nbsp;<a class=\"infinite-modal__link\" href=\"//www.bostonglobe.com\" onclick=\"trackPaywallSubscribe('paywall-home');\"\">Home</a>\n\t\t\t\t</div>\n\t\t\t</div>\n\t\t</div>\n\t</div>\n</div>\n\n<!-- Amtrak  modal -->\n\n<div id=\"amtrak-login\" class=\"white-popup-block paywall-square-meter social-login email-login\">\n  <div class=\"inner\">\n      <h3 class=\"modal-title\">Special Offer for Business Travelers</h3>\n    <span class=\"desktop-text\">Get the day&rsquo;s top stories by 6 am.</span> and breaking news as it unfolds\n\t<div class=\"social-row\"><button id=\"fb-button\" class=\"bg-button--fb\" onclick=\"fblogin()\">Connect with Facebook</button></div>\n\t<div class=\"or\">or</div>\n\t<div class=\"input-container\">\n\t\t<input type=\"text\" name=\"email\" placeholder=\"Enter your email address\" id=\"emailField\" maxLength=\"100\"></input>\n\t\t<button onclick=\"bglobe.social.readEmail()\" class='sub-btn'>Sign up <span class=\"sub-btn--desktop\">& return to story</span></button>\n\t\t<div class=\"error-text hide\">Please enter a valid email</div>\n\t</div>\n \t<div class=\"social-modal-links\"><a href=\"https://www.bostonglobe.com/eom/SysConfig/WebPortal/BostonGlobe/Framework/regi/final-login.jsp\" onClick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','BG Meter Login');\">Subscriber Log in</a> | <a href=\"/tools/help/privacy\" target=\"_blank\">Privacy Policy</a></div>\n   \t\t<span class=\"close-x close-y\">Close</span>\n   </div>\n   \t<div class=\"black-bar\">\n     \t\t<div>\n       \t\t\t<span class=\"bg-icon--white-b-logo\"></span>\n     \t\t</div>\n   \t</div>\n</div>\n\n\n\n<!-- Meter 1 social connect modal -->\n\n<div id=\"email-login\" class=\"white-popup-block paywall-square-meter social-login email-login\">\n  <div class=\"inner\">\n      <h3 class=\"modal-title\">Wake up with<br> today&rsquo;s top stories</h3>\n    <span class=\"desktop-text\">Get <span class=\"bld\">Today\u2019s Headlines</span> every morning and breaking news as it unfolds.</span>\n\t<div class=\"social-row\"><button id=\"fb-button\" class=\"bg-button--fb\" onclick=\"fblogin()\">Connect with Facebook</button></div>\n\t<div class=\"or\">or</div>\n\t<div class=\"input-container\">\n\t\t<input type=\"text\" name=\"email\" placeholder=\"Enter your email address\" id=\"emailField\" maxLength=\"100\"></input>\n\t\t<button onclick=\"bglobe.social.readEmail()\" class='sub-btn'>Sign up <span class=\"sub-btn--desktop\">& return to story</span></button>\n\t\t<div class=\"error-text hide\">Please enter a valid email</div>\n\t</div>\n \t<div class=\"social-modal-links\"><a href=\"https://www.bostonglobe.com/eom/SysConfig/WebPortal/BostonGlobe/Framework/regi/final-login.jsp\" onClick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','BG Meter Login');\">Subscriber Log in</a> | <a href=\"/tools/help/privacy\" target=\"_blank\">Privacy Policy</a></div>\n   \t\t<span class=\"close-x\">Close</span>\n   </div>\n   \t<div class=\"black-bar\">\n     \t\t<div>\n       \t\t\t<span class=\"bg-icon--white-b-logo\"></span>\n     \t\t</div>\n   \t</div>\n</div>\n\n\n<!--  thank you modal -->\n\n<div id=\"social-login-thanks\" class=\"white-popup-block paywall-square-meter social-login email-login\">\n      <div class=\"inner\">\n      <h3 class=\"modal-title\">Thanks for signing up</h3>\n      <a class=\"social-modal__newsletter-link\" href=\"/newsletters?p1=BG_SocialConnect\" target=\"_blank\">Browse our full list of free Globe newsletters</a>\n<!--         <span class=\"desktop-text\">Please check your inbox to confirm your subscription</span> -->\n<button onclick=\"$.magnificPopup.close();\" class='sub-btn'>Return to your story</button>\n       \t<span class=\"close-x\">Close</span>\n     </div>\n    <div class=\"black-bar\">\n     \t\t<div>\n       \t\t\t<span class=\"bg-icon--white-b-logo\"></span>\n     \t\t</div>\n   \t</div>\n</div>\n\n</div>\t<!--  ends display:none; div -->\n<div id=\"meter-limit-met-popup\" class=\"mfp-hide white-popup-block paywall-square-meter\">\n\n  <div class=\"paywall-section-1\">\n  \t\t<a href=\"https://www.bostonglobe.com/eom/SysConfig/WebPortal/BostonGlobe/Framework/regi/final-login.jsp\" class=\"paywall-link\" onclick=\"var s=s_gi('nytbostonglobecom');s.tl(this,'o','BG Fullpage Paywall Login');\">Subscriber Log In</a>\n\t    <h3>We hope you've enjoyed your 5 free articles'</h3>  \n\t    <p class=\"paywall-mobile-link\">Continue reading by subscribing to BostonGlobe.com for <a href=\"http://subscribe.bostonglobe.com/B4685/?p1=BG_Meter_Paywall1\" title=\"mobile\" onClick=\"trackPaywallSubscribe('link')\">just 99&cent;</a>.</p>\n\t    \n\t    <p class=\"paywall-desktop-link\">Continue reading by subscribing to Globe.com for just $.99\u00a2</p>  \n  </div>\n  <div class=\"paywall-section-2\">\n  <div class=\"list-section\">\n    <h2>Stay informed with unlimited access to Boston\u2019s trusted news source.</h2>\n\t    <ul>\n\t      <li>High-quality journalism from the region\u2019s largest newsroom</li>\n\t      <li>Convenient access across all of your devices</li> \n\t      <li>Today\u2019s Headlines daily newsletter</li>\n\t      <li>Subscriber-only access to exclusive offers, events, contests, eBooks, and more</li>\n\t      <li class=\"bold\">Less than 25&#162; a week</li>\n\t    </ul>\n  </div> <!-- /list section -->\n\n\t  <div class=\"image-section\">\n\t    \t<div class=\"paywall-main-device-img\">\n\t    \t\t<img src=\"/img/Device-LockUp-non-transparent.jpg\" alt=\"Marketing image of BostonGlobe.com\" />\n\t    \t</div>\n\t  </div> <!-- /image-section -->\n  </div> <!-- /paywall-section-2 -->\n    \n    <div class=\"paywall-clearfix\"></div>\n\n\t<div class=\"paywall-section-3\">\n\t\t<div class=\"button-section\">\n\t\t\t<form action=\"https://subscribe.bostonglobe.com/B4685/\">\n\t\t         \t<input type=\"hidden\" name=\"rc\" value=\"WW113972\">\n\t\t         \t<input type=\"hidden\" name=\"eglobe_rc\" value=\"WW113972\">\n\t\t         \t<input type=\"hidden\" name=\"p1\" value=\"BG_Meter_Paywall1\">\n\t\t\t\t  \t<button class=\"paywall-full-access-button paywall-desktop-link\" onClick=\"trackPaywallSubscribe('button')\">GET FULL ACCESS NOW</button>\t\t\t  \t\n\t\t\t\t  \t<button class=\"paywall-full-access-button paywall-mobile-link\" onClick=\"trackPaywallSubscribe('mobile')\">GET FULL ACCESS NOW</button>\n\t\t  \t</form>\n\t  \t</div>\n\t  \t\n\t  \t</div> <!-- /paywall-section-3  -->\n  <div class=\"paywall-clearfix\"></div>\n  \n  <div class=\"paywall-section-4\">\n\t  <div class=\"paywall-main-device-img-bottom\">\n\t    <img src=\"/rw/img/Device-LockUp-Mobile-non-transparent.jpg\" alt=\"Marketing image of BostonGlobe.com\" />\n\t  </div>\n  </div>\n\n</div> <div class=\"ad ad-slot-c\" id=\"EXTRA\"></div><!-- Tracking -->\n<!-- stubView3 =  -->\n<!-- sPageNameExt: Hope for devastating child disease comes at a cost: $750,000 a year -->\r\n\t\t\r\n\r\n\t\t\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t\t\r\n\t\t\t\r\n\t\t\r\n\t\t\r\n\t\t\r\n\r\n\t\t\r\n\t\t\r\n\t\t\t\r\n\t\t\t\t\r\n\t\t\t\r\n\t\t\r\n\r\n\t\t\r\n\t\t\t\r\n\t\t\r\n\r\n\t\r\n\t\r\n\t\r\n\t\r\n\t\r\n\t\r\n\t\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\t\r\n\t\t\r\n\t\r\n\t\r\n\r\n\r\n\r\n\r\n<!-- sectionpath /business -->\r\n\r\n\r\n\r\n<!-- pageTitle:  -->\r\n\r\n<!-- Determine sprop_3 -->\r\n\r\n\r\n\r\n\r\n\t\r\n\t\t\r\n\t\r\n\t\r\n\t\t\r\n\t\t\r\n\t\t<!-- authors: Robert Weisman -->\r\n\t\r\n\r\n<script>\r\n\tvar sPageName = (typeof sPageNameOverride != 'undefined') ? sPageNameOverride : 'Business |\u00a0Hope for devastating child disease comes at a cost: $750,000 a year';\r\n\t//if (typeof sPageNameOverride != 'undefined') {\r\n\t//\tsPageName = sPageNameOverride;\r\n\t//}\r\n\tvar sChannel = (typeof sChannelOverride != 'undefined') ? sChannelOverride : 'Business';\r\n\t//var sChannel  = 'Business';\r\n\tvar sProp1    = 'Business';\r\n\tvar sProp3    = 'Robert Weisman';\r\n\tvar sProp4    = 'Standard';\r\n\t//var sProp6    = 'Article Page | Globe Story';\r\n\tvar sProp6    = (typeof sProp6Val != 'undefined') ? sProp6Val : 'Article Page | Globe Story';\r\n\tvar sProp8\t  = '03/28/2017 03:12:38 AM';\r\n\tvar sProp16    = 'none';\r\n\tvar sProp67\t  = '68804080-1364-11e7-8513-19a688a565f6';\r\n\tvar sProp68\t  = 'Hope for devastating child disease comes at a cost: $750,000 a year';\r\n\tvar sProp6a = sProp6;\r\n\tvar sProp1a = sProp1;\r\n\tvar sPageNamea = sPageName;\r\n\tvar sChannela = sChannel;\r\n\t  if ( methode.showPaywall ) {\r\n\t    sChannel  = 'Member Center';\r\n\t    sProp1    = 'Member Center | BGC Registration';\r\n\t    if ( $(window).width() <= 768 ) {\r\n\t      // assume mobile\r\n\t      sPageName = 'Member Center | BGC Registration | Fullpage Paywall Challenge';\r\n\t      sProp6    = 'BGC Registration Page - Fullpage';\r\n\t    } else {\r\n\t      // assume desktop\r\n\t      sPageName = 'Member Center | BGC Registration | Modal Paywall Challenge';\r\n\t      sProp6    = 'BGC Registration Page - Modal';\r\n\t    }\r\n\t  }\r\n\tglobe.extend(globe.analytics.omniture, {\r\n\t  'pageType' : '',\r\n\t  'pageName' : sPageName,\r\n\t  'channel'  : sChannel,\r\n\t  'prop1'    : sProp1,\r\n\t  'prop3'    : sProp3,\r\n\t  'prop4'    : sProp4,\r\n\t  'prop6'    : sProp6,\r\n\t  'prop8'    : sProp8,\r\n\t  'prop16'    : sProp16,\r\n\t  \n\t\t'prop35' : 'logged out',\n\t\t'eVar20' : 'logged out',\n   \t\t'prop42' : 'Metered',\n   \t\t'eVar42' : 'Metered',\n\r\n\t  'eVar16'   : 'none',\r\n\t  'eVar41'   : 'BostonGlobe.com',\r\n\t  'eVar41'   : 'BostonGlobe.com',\r\n\t  'eVar67'   : sProp67,\r\n\t  'prop67'    : sProp67,\r\n\t  'prop68'    : sProp68,\r\n\t  'WT omnituretracking.tag' : 'story'\r\n\t});\r\n</script>\r\n\r\n<noscript>\r\n\t<img src=\"http://newyorktimes.112.2o7.net/b/ss/nytbostonglobecom/1/H.23.3--NS/0?pageName=News%20%7C%20BGC%20Homepage&amp;ch=News&amp;c1=News%20%7C%20BGC%20Homepage&amp;c6=BGC%20Homepage&amp;c41=BostonGlobe.com&amp;v41=BostonGlobe.com\" height=\"1\" width=\"1\" border=\"0\" alt=\"\" />\r\n</noscript>\r\n\r\n\r\n</div>\n</body>\n</html>\n", "title": "Hope for devastating child disease comes at a cost: $750,000 a year", "url": "http://www.bostonglobe.com/business/2017/03/27/spinraza/QnBmQrcmLLfUwvJunn0P8K/story.html", "date": "03-27-2017", "source": "bostonglobe", "text": "Braeden Farrell, 5, operated a wheelchair lift at his family\u2019s home in Newburyport. Both he and his sister, Kernan, 4, have spinal muscular atrophy.\n\nParents of children with a rare disease called spinal muscular atrophy were thrilled two days before Christmas, when regulators approved the first drug to treat the condition that often kills patients before their second birthday.\n\nBut in the three months since, some parents in Massachusetts have fought to get their insurer, Neighborhood Health Plan, to pay for the medicine, an enormously expensive drug called Spinraza and made by Cambridge-based Biogen Inc.\n\nAdvertisement\n\nThe drug\u2019s list price of $750,000 for the first year, and $375,000 annually after that, makes it one of the costliest medicines on the market.\n\nLast week, the parents of a Newburyport girl won a ruling that orders coverage for the drug \u2014 but it appears to be a decision that only applies to their case.\n\nGet Talking Points in your inbox: An afternoon recap of the day\u2019s most important business news, delivered weekdays. Sign Up Thank you for signing up! Sign up for more newsletters here\n\nThe jockeying over reimbursement for Spinraza has become a familiar scenario in the world of breakthrough drugs, reflecting a gulf between patients\u2019 hopes and business realities.\n\nInsurers are demanding stronger evidence to justify the prices of these sorts of drugs. Recently, for example, some have balked at paying for a new drug that prevents strokes and another that treats Duchenne muscular dystrophy. Historically, insurers have usually covered the cost of new medicines for rare diseases with no other treatments.\n\nDrug makers contend that their high prices are justified by the many millions of dollars they sink into research and testing on experimental medicines, many of which never make it to clinical trials.\n\nAdvertisement\n\nIn the case of Spinraza, a state patient protection panel ruled this month that Neighborhood Health was wrong to deny coverage to Kernan Farrell, 4, of Newburyport, who is suffering from a less-critical type of the condition. Her parents, Kristen and Jim Farrell, turned to the Health Policy Commission after losing an in-house appeal to Neighborhood Health.\n\nJohn Blanding/Globe Staff Kristen Farrell, Kernan Farrell, Braeden Farrell, and Jim Farrell at their home in Newburyport.\n\nNeighborhood Health must comply with the decision, said Matthew Kitsos, a spokesman for the commission, but it doesn\u2019t set a precedent; appeals for coverage from other patients with spinal muscular atrophy, known as SMA, will be considered individually.\n\nNeighborhood Health said it will only cover patients with the most severe form of the disease, until it gets more data about how well the drug works.\n\nMeantime, the insurer continues to reject coverage for patients with less severe forms of the condition, which destroys the muscles of more than 10,000 children in the United States.\n\nNeighborhood Health Plan, which lost more than $100 million last year, said it bases its decisions on Spinraza cases purely on medical criteria. The insurer, which is owned by Partners HealthCare, the largest health network in the state, said it will reassess its position as new information about the injectable drug becomes available.\n\nThat means other families are still scrambling to figure out how, or whether, they\u2019ll get access to the new treatment, prescribed by neurologists at Boston Children\u2019s Hospital and other medical centers.\n\nSMA disables the nerve signals controlling muscle movement. In clinical trials, Spinraza helped children stricken with SMA to hold up their heads, sit up, stand on their own, and walk short distances.\n\n\u201cThis is something that could help our son Tyler,\u201d said Boston consultant Doug Hansen, who last week learned he had lost his appeal to Neighborhood Health of its denial of Spinraza coverage for his 11-year-old. \u201cIt could stop or dramatically reduce the progression of the disease.\u201d\n\nTyler was diagnosed with SMA in 2015 after his parents noticed he was falling several times a day. \u201cHe would just drop,\u201d said his mother, Kim. \u201cIt was like his legs would give out.\u201d\n\nDoug Hansen said he, like the Farrells did, will bring his case to the Health Policy Commission unless the insurer changes its decision.\n\nNavigating the bureaucracy around SMA treatments has become a necessary practice for such families as the Farrells. In addition to Kernan, their 5-year-old son, Braeden, also has the condition. Kristen Farrell said that before her children were diagnosed, she had never heard of the disease.\n\nBraeden, who was diagnosed when he was 15 months old, walks with a brace but typically moves about in a wheelchair powered by a small motor. He has been able to receive spinal injections of Spinraza through a clinical trial at Boston Children\u2019s since he was 2\u00bd years old, and it has helped him hold up his head, open a cup lid, and hug his parents. His sister Kernan, diagnosed three weeks after she was born, is still walking but has difficulty balancing and falls frequently.\n\nKeith Bedford/Globe Staff Tyler Hansen, who suffers from spinal muscular atrophy, wrestled with his father Doug at their home in Boston.\n\nNeighborhood Health declined to make executives available for an interview, but in a statement the insurer said it considers only evidence of \u201csafety and efficacy\u201d when ruling on what drugs to cover for which patients.\n\nIt offered a partial explanation for the distinctions it draws in denial letters to the families.\n\nThe insurer\u2019s drug review panel determined that Biogen had demonstrated Spinraza\u2019s effectiveness only for Type 1 SMA patients \u2014 those most severely affected. In its denial letters, Neighborhood Health said Type 3 \u2014 the form that Tyler Hansen and Kernan Farrell have \u2014 wasn\u2019t the focus of Biogen\u2019s study of the drug. It said the clinical data its panel reviewed \u201cdoes not meet our medical necessity criteria\u201d for Type 3, which typically affects children who learn to stand and walk, but eventually lose that ability.\n\nBut when it approved the drug for US sales on Dec. 23, the Food and Drug Administration specified it was approved for all children with SMA. Biogen, in fact, submitted clinical data to the agency showing the drug\u2019s effectiveness in children with less severe forms of the disease, though its tests didn\u2019t compare those patients with others taking a placebo, as they did with Type 1 patients. It is continuing to test the drug on later-onset patients.\n\nThe health plan\u2019s policy is \u201cjust not right,\u201d said Kristen Farrell, a sign language interpreter. \u201cWe feel lucky there\u2019s a treatment now, and there\u2019s good science behind it.\u201d\n\nKeith Bedford/Globe Staff Tyler Hansen.\n\nIn its statement, Neighborhood Health said it could not discuss specific cases because of privacy concerns. It said the insurer\u2019s pharmacy and therapeutics committee, staffed by independent doctors and pharmacists, followed a \u201crigorous process\u201d in concluding it should cover Spinraza only for Type 1 patients.\n\nDr. Basil Darris, director of the SMA program at Boston Children\u2019s, who ran the hospital\u2019s clinical trials of Spinraza, said the existing data are strong enough for him to prescribe the drug for all patients with the disease.\n\n\u201cWe\u2019re happy that we now have a drug for these patients, and we can see the benefits,\u201d Darris said. \u201cThere\u2019s an urgency here.\u201d\n\nWhile insurers have stepped up their criticism of high drug prices, many \u2014 including Aetna and United HealthGroup, two of the nation\u2019s biggest carriers \u2014 are covering Spinraza for all patients. Biogen chief executive Michel Vounatsos told a health care conference earlier this month that more than 50 regional and national health plans will pay for the drug. Other insurers, including about 20 Medicaid plans nationally, are evaluating Spinraza claims case by case.\n\nThat\u2019s the approach the three largest Massachusetts health insurers \u2014 Blue Cross and Blue Shield, Harvard Pilgrim, and Tufts Health Plan \u2014 are taking for now. All five Blue Cross members in Massachusetts who requested Spinraza \u2014 including some Type 3 patients \u2014 were approved for coverage, said senior vice president Jay McQuaide.\n\nBiogen spokesman Todd Cooper said the cost of Spinraza is \u201cin line with what we\u2019ve seen in other orphan therapies\u201d \u2014 new drugs that treat rare genetic diseases for which there are no other treatments. The company subsidizes the cost to qualified patients who don\u2019t have insurance, but the subsidies don\u2019t cover the steep cost of the injection procedure itself.", "images": ["http://c.o0bg.com/rf/image_r/Boston/2011-2020/2017/03/21/BostonGlobe.com/Business/Images/Bedford_170320_SPINAL_ATROPHY_021.r.jpg", "http://www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/27/BostonGlobe.com/Politics/Images/654568498.jpg", "http://c.o0bg.com/rf/image_r/Boston/2011-2020/2017/03/21/BostonGlobe.com/Business/Images/Bedford_170320_SPINAL_ATROPHY_016.r.jpg", "http://www.bostonglobe.com/img/Device-LockUp-non-transparent.jpg", "http://www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/02/BostonGlobe.com/Metro/Images/Bedford_170223_CAITLYN_011.jpg", "http://www.bostonglobe.com/rf/image_r/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza5biz.r.jpg", "http://www.bostonglobe.com/img/masthead/lockup.png", "http://www.bostonglobe.com/rw/img/Device-LockUp-Mobile-non-transparent.jpg", "http://www.bostonglobe.com/img/masthead/newspaper.png", "http://googleads.g.doubleclick.net/pagead/viewthroughconversion/1071256246/?value=0&guid=ON&script=0", "https://www.facebook.com/tr?id=884869448226452&ev=PageView&noscript=1", "http://newyorktimes.112.2o7.net/b/ss/nytbostonglobecom/1/H.23.3--NS/0?pageName=News%20%7C%20BGC%20Homepage&ch=News&c1=News%20%7C%20BGC%20Homepage&c6=BGC%20Homepage&c41=BostonGlobe.com&v41=BostonGlobe.com", "http://www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza5biz.jpg", "http://c.o0bg.com/rf/image_r/Boston/2011-2020/2017/03/22/BostonGlobe.com/Business/Images/blanding03211723spinraza2biz.r.jpg", "http://www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/26/BostonGlobe.com/National/Images/united.jpg", "http://www.bostonglobe.com/rf/image_585w/Boston/2011-2020/2017/03/15/BostonGlobe.com/Metro/Images/kreiter_bombingsurvivor2_met.jpg"], "videos": []}